title: Changing M3G/M6G ratios and pharmacodynamics in a cancer patient during long-term morphine treatment.
abstract: A cancer patient receiving long-term oral sustained-release morphine treatment and periodically presenting with unusually high plasma M3G/M6G ratios is described. We found the patient's formation of M6G more unstable and perhaps delayed compared to the formation of M3G. There is no apparent explanation for this phenomenon and the high M3G/M6G ratios had no implications for the patient's pain experience or side effects from the morphine treatment.
authors.affiliation: Multidiciplinary Pain Center, Herlev University Hospital, Herlev, Denmark
authors.forename: Gertrud
authors.initials: G
authors.lastname: Andersen
authors.forename: Lona L
authors.initials: LL
authors.lastname: Christrup
authors.forename: Per
authors.initials: P
authors.lastname: Sjøgren
authors.forename: Steen Honoré
authors.initials: SH
authors.lastname: Hansen
authors.forename: Niels-Henrik
authors.initials: NH
authors.lastname: Jensen
mesh_terms: D000701:Analgesics, Opioid / Q000494:pharmacology* / Q000627:therapeutic use*; D000697:Central Nervous System Stimulants / Q000097:blood* / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009020:Morphine / Q000494:pharmacology* / Q000627:therapeutic use*; D009022:Morphine Derivatives / Q000097:blood* / Q000494:pharmacology*; D010146:Pain / Q000097:blood / Q000188:drug therapy*; D011471:Prostatic Neoplasms / Q000097:blood / Q000150:complications*; D013997:Time Factors
chemical_list: D000701:Analgesics, Opioid; D000697:Central Nervous System Stimulants; D009022:Morphine Derivatives; C035349:morphine-6-glucuronide; D009020:Morphine; C018108:morphine-3-glucuronide